How Rapid Is Weight Loss With Farxiga? Honest Evidence Review

Slow and modest. Farxiga (dapagliflozin) causes about 1-3 kg of weight loss over 6-12 months — a side effect of the drug's mechanism (urinary glucose excretion of roughly 70-80 g/day, a caloric loss of approximately 280 kcal/day) that is partially offset by compensatory hunger, with weight plateauing by approximately month 6. Farxiga is not FDA-approved for weight loss. Its FDA-approved indications are type 2 diabetes glycemic control (January 2014), reduction of cardiovascular death and heart-failure hospitalization in adults with type 2 diabetes and established cardiovascular disease or multiple CV risk factors (October 2019, based on DECLARE-TIMI 58^[1]), heart failure with reduced ejection fraction with or without diabetes (May 2020, based on DAPA-HF^[2]), chronic kidney disease at risk of progression with or without diabetes (April 2021, based on DAPA-CKD^[3]), and heart failure across the full ejection-fraction range including HFmrEF and HFpEF (May 2023, based on DELIVER^[4]). Magnitude versus the dedicated obesity medications is in a different category entirely: Wegovy (semaglutide 2.4 mg) produced −14.9% body weight in STEP-1^[8] and Zepbound (tirzepatide 15 mg) produced −20.9% in SURMOUNT-1^[9] — roughly 5-10× more than Farxiga. If your goal is weight loss alone, Farxiga is the wrong tool. If your goal is T2D glycemic control plus heart-failure or kidney protection — with modest weight loss as a welcome side effect — Farxiga is an evidence-anchored choice. Here is the verified evidence.

The honest summary

• Weight loss magnitude: approximately 1-3 kg placebo-adjusted across the dapagliflozin trials. The Bolinder 2012 24-week add-on-to-metformin body-composition trial^[5] reported −2.96 kg with dapagliflozin 10 mg vs −0.88 kg with placebo, with DEXA confirming that roughly two-thirds of the lost weight was fat mass (including trunk fat). The Bailey 2010 pivotal phase-3 add-on-to-metformin trial^[6] reported approximately −2.2 kg at the 10 mg dose vs −0.9 kg with placebo. The Cheong 2022 meta-analysis of 116 SGLT2 RCTs^[7] pooled a class-wide weight reduction of approximately 2 kg.
• Mechanism: Farxiga blocks SGLT2 in the proximal renal tubule, causing the kidneys to excrete roughly 70-80 g of glucose per day in urine. That is a caloric loss of approximately 280 kcal/day — theoretically ~1 kg of fat per month if nothing else changed. In practice, the body compensates by increasing food intake, so the realized weight loss is smaller (~1-3 kg in 12-24 weeks).
• Plateau: weight loss on Farxiga plateaus by approximately 6 months. After that, weight remains stable rather than progressively declining. The Cheong 2022 meta-analysis^[7] documented this plateau across long-duration SGLT2 trials.
• FDA-approved indications: T2D glycemic control (January 2014), CV risk reduction in T2D + CVD or CV risk (October 2019, DECLARE-TIMI 58^[1]), HFrEF (May 2020, DAPA-HF^[2]), CKD (April 2021, DAPA-CKD^[3]), full-spectrum heart failure including HFmrEF/HFpEF (May 2023, DELIVER^[4]). Obesity is not on this list.
• Magnitude vs GLP-1s: Wegovy STEP-1 reported −14.9% body weight at 68 weeks^[8]; Zepbound SURMOUNT-1 reported −20.9% at 72 weeks^[9]. For a 100-kg starting weight that is −15 kg and −21 kg respectively. Farxiga at 1-3 kg is in a different magnitude category.
• Side effects: genital mycotic infections (3-5× baseline rate, more common in women), urinary tract infections, volume depletion/dehydration, rare euglycemic diabetic ketoacidosis (FDA Drug Safety Communication 2015 covers the SGLT2 class), very rare Fournier's gangrene (FDA boxed warning 2018 covers the SGLT2 class).
• Bottom line: Farxiga causes real but modest weight loss as a side effect. It is a good drug — for T2D, heart failure (full ejection-fraction spectrum), or CKD. It is the wrong drug if your goal is weight loss alone. The GLP-1s do that job at an order of magnitude greater effect.

What is Farxiga?

Farxiga is the brand name for dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor manufactured by AstraZeneca. The drug is taken as a once-daily oral tablet, typically at 5 mg or 10 mg. It was first approved by the FDA in January 2014 for glycemic control in adults with type 2 diabetes. Since then, the indication list has expanded substantially based on a succession of large outcomes trials:

• January 2014: initial FDA approval for type 2 diabetes (glycemic control, as monotherapy or as add-on to metformin, sulfonylureas, pioglitazone, or insulin).
• October 2019: reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and either established cardiovascular disease or multiple CV risk factors, based on DECLARE-TIMI 58^[1]. This expanded dapagliflozin's indication from a glucose-lowering drug to a cardiovascular-risk drug.
• May 2020: reduce the risk of CV death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), with or without diabetes — based on DAPA-HF^[2]. This was the first SGLT2 inhibitor to earn a heart-failure indication independent of diabetes status.
• April 2021: reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression, with or without diabetes — based on DAPA-CKD^[3]. The first SGLT2 to earn a dedicated CKD indication.
• May 2023: expanded heart-failure indication to cover adults with heart failure across the full ejection- fraction range, including HFmrEF and HFpEF, based on DELIVER^[4].

Conspicuously absent from that list: obesity, overweight, chronic weight management, weight loss. The FDA has never approved Farxiga for weight loss as a primary or co-primary indication. The weight loss that occurs on Farxiga is a documented side effect of the SGLT2 mechanism, not a therapeutic goal of the drug.

For the broader landscape of FDA-approved obesity pharmacotherapy — the GLP-1s, the combination products, and the older non-GLP-1 options — see our full GLP-1 medication reference, which has an entire section explaining why SGLT2 inhibitors like Farxiga are not GLP-1 medications and are a different drug class entirely. For the head-to-head map between the two classes, see our SGLT2-vs-GLP-1 deep-dive. For the sister-drug article on the other major SGLT2 inhibitor, see our Jardiance (empagliflozin) weight loss evidence review — the magnitudes and verdicts are very similar.

How Farxiga causes weight loss — the SGLT2 mechanism

The SGLT2 cotransporter sits in the proximal convoluted tubule of the kidney. Its job is to reabsorb glucose from the glomerular filtrate back into the bloodstream. In a person without diabetes, roughly 180 g of glucose is filtered per day, and nearly all of it is reabsorbed by SGLT2 (~90%) and SGLT1 (~10%). When SGLT2 is blocked pharmacologically by dapagliflozin or another SGLT2 inhibitor, that reabsorption fails, and the unreabsorbed glucose ends up in the urine. In patients with type 2 diabetes (who typically have elevated blood glucose and therefore filter more glucose), Farxiga causes the kidneys to excrete approximately 70-80 g of glucose per day in urine.

Glucose has a caloric density of approximately 4 kcal/g. So a daily glucose loss of ~70-80 g represents a caloric loss of approximately 280-320 kcal/day. In a first- order energy-balance calculation, that is roughly 8,000 kcal/month, which corresponds to about 1 kg of body fat (since body fat is approximately 7,700 kcal/kg). Over a year, naively, that would predict ~12 kg of weight loss.

The actual observed weight loss on Farxiga is substantially smaller — about 1-3 kg, plateauing by 6 months. Why the gap between the theoretical caloric loss and the observed weight loss? The body compensates. Multiple mechanistic studies have documented that SGLT2 inhibition triggers a compensatory increase in food intake (hyperphagia), partly mediated by central appetite-regulating circuits that detect the glucose loss as a signal of energy deficiency. People on SGLT2 inhibitors eat modestly more, and the realized caloric deficit is much smaller than the urinary glucose loss alone would predict.

This compensatory hyperphagia is precisely the problem that GLP-1 receptor agonists solve. The GLP-1 class works centrally to reduce appetite while producing much smaller peripheral caloric losses. The net energy deficit on a GLP-1 is therefore much larger than the net energy deficit on an SGLT2 inhibitor, even though the peripheral mechanisms are completely different. See our overview at semaglutide and tirzepatide for the GLP-1 mechanism and dosing detail.

How much weight loss in the dapagliflozin trials

The published dapagliflozin trial program is large and consistent on the weight-loss question. Selected key data:

Bailey 2010 (Lancet, n=546, 24 weeks)^[6]. The first pivotal phase-3 dapagliflozin trial: dapagliflozin 2.5 mg, 5 mg, or 10 mg added to metformin vs placebo added to metformin in T2D patients with inadequate glycemic control on metformin alone. A1c reductions were dose- responsive (−0.67% at 2.5 mg, −0.70% at 5 mg, −0.84% at 10 mg). Body weight changes: approximately −2.2 kg at the 10 mg dose versus approximately −0.9 kg with placebo. Weight effects were apparent within weeks and stable through the 24-week trial.

Bolinder 2012 (J Clin Endocrinol Metab, n=182, 24 weeks)^[5]. The cleanest dedicated body- composition study of dapagliflozin. Patients on metformin with inadequate A1c received dapagliflozin 10 mg or placebo added on, with DEXA scanning to partition the weight loss into fat mass, lean mass, and bone. Body weight: dapagliflozin −2.96 kg vs placebo −0.88 kg (placebo-adjusted −2.08 kg, p<0.0001). Total fat mass decreased by approximately 1.5-2.0 kg, with documented reductions in trunk-fat (visceral and subcutaneous) territory. This is the trial most often cited to support the claim that SGLT2-driven weight loss is predominantly fat-mass loss rather than fluid loss.

DECLARE-TIMI 58 (Wiviott 2019 NEJM, n=17,160)^[1]. The pivotal cardiovascular outcomes trial in T2D patients with either established CVD or multiple CV risk factors — a broader population than EMPA-REG had used. Primary 3-point MACE (HR 0.93, 95% CI 0.84-1.03, p=0.17 for superiority but noninferior to placebo for safety). The coprimary endpoint of CV death or hospitalization for heart failure was reduced: HR 0.83 (95% CI 0.73-0.95, p=0.005), driven primarily by a 27% reduction in HF hospitalization (HR 0.73, 95% CI 0.61-0.88). Body weight showed a placebo-adjusted reduction of approximately 1.8 kg sustained through the median 4.2-year follow-up.

DAPA-HF (McMurray 2019 NEJM, n=4,744)^[2]. Dapagliflozin vs placebo in patients with established HFrEF (LVEF ≤40%), with or without diabetes. The primary composite of worsening heart failure or cardiovascular death occurred in 16.3% (dapagliflozin) vs 21.2% (placebo); HR 0.74 (95% CI 0.65-0.85, p<0.001). Body weight changes were modest and consistent with the T2D trials, in the 1-2 kg range.

DAPA-CKD (Heerspink 2020 NEJM, n=4,304)^[3]. Dapagliflozin vs placebo in adults with CKD (eGFR 25-75, urinary albumin-to-creatinine ratio 200-5000), with or without diabetes. The primary composite of a ≥50% sustained decline in eGFR, end-stage kidney disease, or renal or cardiovascular death occurred in 9.2% (dapagliflozin) vs 14.5% (placebo); HR 0.61 (95% CI 0.51-0.72, p<0.001). The trial stopped early for overwhelming benefit. Weight effects in the same 1-2 kg range as the T2D and HFrEF trials.

DELIVER (Solomon 2022 NEJM, n=6,263)^[4]. Dapagliflozin vs placebo in adults with heart failure and LVEF >40% (HFmrEF and HFpEF), with or without diabetes. Primary composite of worsening heart failure or cardiovascular death: HR 0.82 (95% CI 0.73-0.92, p<0.001). Combined with DAPA-HF, DELIVER made dapagliflozin the second drug after empagliflozin to demonstrate heart-failure benefit across the full ejection-fraction spectrum, and led to the FDA's expanded HF label in May 2023. Weight effects again modest and consistent with the broader dapagliflozin program.

Cheong 2022 (Obesity, meta-analysis of 116 RCTs)^[7]. The largest pooled analysis of SGLT2 inhibitors and weight. Across the class (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin), the pooled placebo-adjusted weight reduction was approximately 2 kg, with a consistent class effect and a clear plateau by ~6 months. Cheong is the canonical citation for the magnitude question: SGLT2 inhibitors as a class produce ~2 kg of weight loss; dapagliflozin is not exceptional within the class.

Taken together, the dapagliflozin trial program supports a clear, narrow conclusion: Farxiga produces approximately 1-3 kg of weight loss in adults with T2D or with HF or with CKD, sustained for the duration of the trials but plateauing at roughly 6 months. The effect is real, reproducible, and modest.

Why weight loss plateaus on Farxiga

The plateau effect is one of the most clinically important features of SGLT2 inhibitor weight loss. Patients often start Farxiga, lose a few pounds in the first 2-3 months, and then find that the scale stops moving even though they are still taking the drug and the drug is still doing its job. They sometimes interpret the plateau as a sign that the drug has “stopped working,” which is not what is happening.

What is happening: the urinary glucose excretion continues at the same rate as long as the patient is taking the drug, but compensatory hyperphagia matches the caloric loss. In thermodynamic terms, energy in goes up by approximately the same amount that energy out (via urine glucose) goes up, and the net energy balance returns to neutral. Body weight stabilizes at a new, slightly lower setpoint.

Several mechanistic studies have characterized this. The compensatory hunger is partly mediated through central appetite-regulating circuits that sense the chronic glucose loss as an energy deficiency signal, and partly through increases in counter-regulatory hormones (glucagon, growth hormone). The end result is that the realized caloric deficit on long-term SGLT2 therapy is much smaller than the urinary glucose loss alone would predict.

Clinically, this means three things for patients:

• The Farxiga weight loss is front-loaded. Most of it happens in the first 12-24 weeks. After that, the scale stabilizes.
• Combining Farxiga with caloric restriction, with structured exercise, or with a GLP-1 can produce more weight loss than Farxiga alone — because the additional intervention works around the compensatory hyperphagia.
• Stopping Farxiga after the weight loss has been achieved typically causes regain of most or all of the lost weight, because the urinary glucose excretion stops and the compensatory eating pattern persists.

Farxiga vs GLP-1s for weight loss — the magnitude gap

For people whose primary goal is weight loss, the most important comparison is between Farxiga and the FDA-approved obesity medications. The published trial results put the two classes in completely different magnitude categories:

• Farxiga (dapagliflozin): approximately 1-3 kg placebo-adjusted across pivotal trials. As a percentage of starting body weight (typical baseline ~85-90 kg in trial populations), that is approximately 1-3%.
• Wegovy (semaglutide 2.4 mg weekly): STEP-1 reported −14.9% body weight at 68 weeks in adults with overweight or obesity without diabetes^[8]. For a 100-kg starting weight, that is approximately −15 kg.
• Zepbound (tirzepatide 15 mg weekly): SURMOUNT-1 reported −20.9% body weight at 72 weeks^[9]. For a 100-kg starting weight, that is approximately −21 kg. See our tirzepatide brand disambiguation for the Mounjaro/Zepbound distinction.
• Ozempic (semaglutide 1-2 mg weekly, T2D indication): approximately 4-6 kg over 30 weeks at full dose, smaller than Wegovy because the dose is lower.
• Mounjaro (tirzepatide 5-15 mg weekly, T2D indication): approximately 6-12 kg over 40 weeks depending on dose, in T2D patients.

On a head-to-head magnitude basis, Wegovy produces roughly 5-10× more weight loss than Farxiga, and Zepbound produces roughly 7-15× more. There is no realistic dose or duration of Farxiga that closes this gap. The class effect of SGLT2 inhibitors caps out at approximately the level captured in the Cheong 2022 meta-analysis^[7]: ~2 kg, plateauing by 6 months.

For T2D patients with both obesity and cardiovascular or kidney risk, the answer is increasingly both — combine an SGLT2 inhibitor (for cardio-renal protection) with a GLP-1 (for substantial weight loss and additional cardiovascular benefit). The ADA 2025 Standards of Care recommend this combination for patients with established ASCVD, heart failure, or CKD whose A1c is more than 1.5-2.0 percentage points above goal. See our SGLT2-vs-GLP-1 deep-dive for the combination evidence base.

For lean-mass preservation context, GLP-1-driven weight loss is a mix of fat mass and lean mass, and pairing the medication with resistance training plus adequate protein is essential. SGLT2-driven weight loss on Farxiga is also mixed but skews toward fat-mass loss according to the Bolinder 2012 DEXA data^[5], and the absolute amount of lean mass at stake is much smaller because the absolute weight loss is much smaller. See our best protein powder for weight loss on a GLP-1 review for the protein-and-resistance-training pattern that applies primarily to GLP-1 patients.

Farxiga vs Jardiance — small but real class differences

Patients frequently ask whether Farxiga or Jardiance is “better” for weight loss. The short answer: clinically equivalent, with magnitudes in the same 1-3 kg range across both drugs, and a class-effect plateau by month 6. The Cheong 2022 meta-analysis^[7] pooled empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin and found no meaningful between-agent differences in weight loss magnitude.

Where the two drugs differ slightly:

• Indication breadth: Jardiance and Farxiga have largely overlapping FDA labels — T2D, CV-risk reduction in T2D, HFrEF, HFpEF/HFmrEF, and CKD. Empagliflozin earned the first CV-mortality indication (EMPA-REG OUTCOME 2015), while dapagliflozin earned the first dedicated HFrEF (DAPA-HF 2019) and first dedicated CKD (DAPA-CKD 2020) indications independent of diabetes status. By 2026 the two labels are functionally equivalent for most prescribing scenarios.
• Dose: Farxiga is typically dosed at 10 mg once daily for T2D, HF, and CKD (5 mg as a starting dose in some cases). Jardiance is dosed at 10 mg or 25 mg once daily.
• eGFR thresholds: the two products have slightly different lower eGFR thresholds for initiation and continuation, reflecting their separate kidney-trial enrollment criteria. Specifics should be checked against the current prescribing information.
• Insurance coverage: for most patients in 2026 the bigger driver of drug selection is which agent their formulary prefers. Both are still brand-name (no US generics as of 2026) and retail cash price runs in the $500-700/month range.

For a sister-drug comparison and the detailed empagliflozin evidence base, see our Jardiance weight loss evidence review — the verdict and magnitudes track Farxiga's very closely. For the broader class-vs-GLP-1 comparison, see the SGLT2-vs-GLP-1 hub.

Side effects and safety

The dapagliflozin safety profile is broadly favorable and well-characterized after more than a decade on market. The most common and most clinically important adverse events:

• Genital mycotic infections (yeast infections): the most common SGLT2 side effect, occurring in approximately 5-10% of patients (vs 1-2% on placebo). Women are affected roughly 2-3× more often than men. Usually responds to topical antifungals; recurrent cases may need switching off the SGLT2 class.
• Urinary tract infections: modestly increased incidence (~3-5% vs ~2% on placebo). Severe UTIs and pyelonephritis are rare but real.
• Volume depletion and dehydration: the SGLT2- driven osmotic diuresis can cause hypotension, dizziness, and dehydration, especially in elderly patients and those on loop diuretics. Dose reductions of concomitant diuretics are often recommended at initiation.
• Euglycemic diabetic ketoacidosis (DKA): rare but serious. The FDA issued a Drug Safety Communication in May 2015 highlighting cases of DKA at normal or near- normal blood glucose levels in SGLT2 users. Risk factors include insulin dose reductions, low-carbohydrate or ketogenic diets, severe illness, dehydration, surgery, and alcohol use. Patients should be educated to stop the drug and seek care if they develop nausea, vomiting, abdominal pain, or rapid breathing.
• Fournier's gangrene: a very rare but serious necrotizing fasciitis of the perineum. The FDA added a boxed warning to the SGLT2 class in August 2018 based on 12 postmarketing cases across the class. Postmarketing reports remain very rare, but the severity is high.
• Acute kidney injury: early concerns about AKI on SGLT2 initiation have largely been allayed by the DAPA-CKD, EMPA-KIDNEY, and CREDENCE trials, which all showed long-term kidney protection. Transient eGFR dips on initiation are common but reverse with continued use.
• Bladder cancer signal: small numerical imbalance in early dapagliflozin trials prompted FDA attention, but subsequent pharmacovigilance has not confirmed a meaningful class effect. Current FDA labeling notes the historical signal without listing bladder cancer as a contraindication.
• Hypoglycemia: low risk with Farxiga monotherapy because the mechanism is glucose-dependent (urine glucose excretion only happens when blood glucose is above the renal threshold). Hypoglycemia risk increases when Farxiga is added to insulin or sulfonylureas; dose reductions of those agents are commonly needed.

Contraindications: type 1 diabetes (DKA risk), severe renal impairment below the eGFR thresholds in the prescribing information, history of recurrent severe genital infections, prior Fournier's gangrene. Pregnancy is not a formal contraindication but the drug is generally avoided in pregnancy due to limited data.

Should you use Farxiga for weight loss?

The honest answer is no, with carefully defined exceptions:

• If your primary goal is weight loss and you do not have T2D, HFrEF, HFpEF/HFmrEF, or CKD: Farxiga is the wrong tool. The magnitude is too small (1-3 kg) and the drug is not FDA-approved for this indication. The right tools are the FDA-approved obesity medications — semaglutide (Wegovy), tirzepatide (Zepbound), or the older options (phentermine-topiramate / Qsymia, naltrexone- bupropion / Contrave, liraglutide / Saxenda, orlistat). See our full GLP-1 reference for the landscape.
• If you have T2D and you want both glycemic control and modest weight loss: Farxiga is a reasonable first-line or second-line choice (per ADA 2025 Standards of Care). The 1-3 kg of weight loss is a useful side effect; the A1c reduction of ~0.5-0.8% is the primary indication. If you also have established CVD, HF, or CKD, the cardio- renal indications make the case even stronger.
• If you have HFrEF, HFmrEF, or HFpEF (with or without diabetes): Farxiga has a clear cardiovascular indication independent of weight or A1c. Use it for the heart-failure benefit; the modest weight loss is a bonus.
• If you have CKD at risk of progression: Farxiga has a clear kidney indication (DAPA-CKD^[3]) and the renal-protective effect is the dominant reason to prescribe it. The weight loss is, again, a side benefit.
• If you have T2D + obesity + ASCVD/HF/CKD: the increasingly recommended approach is combination therapy: Farxiga (or another SGLT2) for cardio-renal protection, plus a GLP-1 (semaglutide, tirzepatide) for substantial weight loss and additional cardiovascular benefit. The two classes have non-overlapping mechanisms and are commonly combined in real-world T2D management.

Beyond these scenarios, the off-label use of Farxiga for weight loss alone is not supported by the evidence base. The weight effect is too small relative to the FDA-approved obesity medications, the side-effect profile (yeast infections, UTIs, rare DKA) is not zero, and the financial cost (~$500-700/month at retail) is not trivial. Patients considering Farxiga for weight loss alone should reconsider and look at the GLP-1 class instead.

How Farxiga fits in our coverage

Farxiga sits at the edge of our coverage scope. We focus primarily on weight-loss pharmacotherapy — the GLP-1 receptor agonists and the older obesity medications — because that is where the strongest evidence base for clinically meaningful weight loss is. Farxiga and the SGLT2 class come into our coverage because patients frequently ask about them as weight-loss options. The short answer: they produce real but modest weight loss; they are not first-line for weight loss alone; they are a strong choice when the primary indication is T2D, heart failure, or kidney disease.

Related research and tools:

• Does Jardiance cause weight loss? Honest evidence review — the sister-drug article covering empagliflozin. The magnitudes and verdicts track Farxiga's very closely
• SGLT2 inhibitors vs GLP-1s: Jardiance, Farxiga, and the head-to-head map — the parent comparison hub covering all three major SGLT2 inhibitors against the GLP-1 class
• Full GLP-1 medication reference — the comprehensive list of GLP-1 receptor agonists, with the “SGLT2 inhibitors are NOT GLP-1 RAs” section explaining the class distinction
• Mounjaro vs Zepbound: same drug, different brands — the tirzepatide article. Tirzepatide produces ~21% body weight loss vs Farxiga ~1-3%
• Semaglutide drug page — the GLP-1 we compare Farxiga against most often
• Tirzepatide drug page — the dual GIP/GLP-1 agonist with the largest weight- loss magnitude in published trials
• Best protein powder for weight loss on a GLP-1 — protein adequacy for lean-mass preservation during medication-driven weight loss. More relevant to GLP-1 patients than to Farxiga patients because the absolute weight loss is much larger
• Is salmon good for weight loss? Honest evidence review — a parallel food-evidence article in the same editorial pattern
• Are potatoes good for weight loss? Honest evidence review — another parallel food-evidence article

Bottom line

• Yes, Farxiga (dapagliflozin) causes weight loss — approximately 1-3 kg, on average, in pivotal trials. The mechanism is urinary glucose excretion (~70-80 g glucose/day, ~280 kcal/day caloric loss), partially offset by compensatory hyperphagia.
• The weight effect plateaus by approximately 6 months. After that, weight remains stable but does not progressively decline.
• Farxiga is not FDA-approved for weight loss. Its FDA-approved indications are T2D glycemic control (2014), CV-event reduction in T2D + CVD or CV risk (2019), HFrEF (2020), CKD (2021), and full-spectrum heart failure (2023). The cardiovascular and kidney benefits are the dominant reasons to prescribe Farxiga.
• Magnitude vs GLP-1s: Wegovy STEP-1 produced −14.9% body weight at 68 weeks^[8]; Zepbound SURMOUNT-1 produced −20.9% at 72 weeks^[9]. Farxiga at 1-3 kg is in a different category — roughly 5-10× smaller.
• For patients with T2D plus obesity plus cardio-renal risk, combination SGLT2 + GLP-1 is increasingly the standard of care per ADA 2025. Use Farxiga for the cardio-renal benefit; use the GLP-1 for the substantial weight loss.
• Side effects: genital mycotic infections (most common), UTIs, volume depletion, rare euglycemic DKA, very rare Fournier's gangrene. Generally favorable safety after a decade-plus on market.
• If your primary goal is weight loss and you do not have T2D, HF, or CKD, Farxiga is the wrong tool. The FDA-approved obesity medications are the right tools.

Important disclaimer. This article is educational and does not constitute medical advice. Decisions about whether to start, continue, or stop Farxiga (dapagliflozin) should be made with your prescribing clinician, who can weigh your specific T2D status, cardiac and renal function, concomitant medications (especially insulin, sulfonylureas, and diuretics), pregnancy plans, and risk factors for euglycemic DKA or genital infections. Patients with type 1 diabetes should not take SGLT2 inhibitors outside of specific monitored protocols due to DKA risk. Patients on low-carbohydrate or ketogenic diets, those undergoing surgery, and those with acute illness should discuss SGLT2 dose-holds with their clinician. Every primary source cited here was independently verified against PubMed E-utilities on 2026-05-16. Specific hazard ratios, confidence intervals, and weight-loss magnitudes cited are from published abstracts and primary publications; full-text endpoints may differ slightly and should be confirmed against the trial publication for any critical clinical decision.

Last verified: 2026-05-16. Next review: every 12 months, or sooner if a major new SGLT2 outcomes trial publishes or if Farxiga receives a new FDA indication.